Medical Advocates
Nevirapine (Viramune)
 
Journal Citations:  Adolescent/Adult Indications
 
General Reports
NVP/3TC 
NVP/EFV/DDI 
 NVP/Etravirine
NVP/TNF/EMT
NVP/STV/3TC
NVP/ZDV/DDI vs STV/DDI
NVP/ZDV/3TC
STV/DDI/NVP
Miscellaneous  Combinations		 Post-Exposure Prophylaxis
Dosing
Adherence
Treatment Strategies
 



 
NVP Main Page Journal Main Page Main New/Newsworthy  Home Page
Last Update:  October 01, 2016
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
General Reports
           
 
Lipid-based nutrient supplements do not affect efavirenz but lower plasma nevirapine concentrations in Ethiopian adult HIV patients.
Abdissa A, Olsen MF, Yilma D, et al
HIV Med. 2015 May 13.
 Abstract  

FULL-TEXT ARTICLE
Cytochrome P450 2B6 genetic variants are associated with plasma nevirapine levels and clinical response in HIV-1 infected Kenyan women: a prospective cohort study.
 Oluka MN, Okalebo FA, Guantai AN, et al
AIDS Res Ther. 2015 Apr 15;12:10.
Paper

FULL-TEXT ARTICLE
 Nevirapine-Based Regimens in HIV-Infected Antiretroviral-Naive Patients: Systematic Review and Meta-Analysis of Randomized Controlled Trials.
 Kawalec P, Kryst J, Mikrut A, Pilc A.  
PLoS One. 2013 Oct 7;8(10):e76587.
Paper

FULL-TEXT PDF ARTICLE(pdf of article must be downloaded from the publication website)
 Differential responses of human hepatocytes to the non-nucleoside HIV-1 reverse transcriptase inhibitor nevirapine.
 Fang JL, Beland FA.
J Toxicol Sci. 2013;38(5):741-52"
Paper

Long-Term Benefits of Nevirapine-Containing Regimens: Multicenter Study with 506 Patients,
Followed-Up a Median of 9 Years.
 Podzamczer D, Tiraboschi JM, Mallolas J, et al
Curr HIV Res. 2012 Jun 21.
 Abstract  

Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
 Takuva S, Evans D, Zuma K, Okello V, Louwagie G.
Pan Afr Med J. 2013 May 3;15:5
Abstract

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.
 The HIV-CAUSAL Collaboration.
AIDS. 2012 Apr 26.
Abstract


A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naïve patients.
 Dejesus E, Mills A, Bhatti L, et al
 Int J Clin Pract. 2011 Oct 14.
 Abstract

Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study).
 Podzamczer D, Andrade-Villanueva J, Clotet B,  et al
HIV Med. 2011 Apr 24.
 Abstract

Higher efficacy of nevirapine than efavirenz to achieve HIV-1 plasma viral load below 1 copy/ml.
 Haïm-Boukobza S, Morand-Joubert L, Flandre P,  et al
AIDS. 2010 Dec 13.
 Abstract

Protein Adducts As Prospective Biomarkers of Nevirapine Toxicity.
 Antunes AM, Godinho AL, Martins IL, et al
Chem Res Toxicol. 2010 Sep 1
 Abstract

Long-Term Effectiveness and Safety Outcomes in HIV-1-Infected Patients After a Median Time of 6 Years on Nevirapine.
 Rodríguez-Arrondo F, Aguirrebengoa K, Portu J, et al
 Curr HIV Res. 2009 Sep;7(5):526-532
 Abstract

Pharmacokinetics of Nevirapine and Lamivudine in Patients with HIV-1 Infection.
Sabo J, Lamson M, Leitz G, et al  
 AAPS PharmSci 2000;2(1):E1
 Abstract

 
NVP/3TC
           
  Pharmacokinetics of Nevirapine and Lamivudine in Patients with HIV-1 Infection.
Sabo J, Lamson M, Leitz G, et al  
 AAPS PharmSci 2000;2(1):E1
 Abstract 		 
NVP/3TC
           
  Pharmacokinetics of Nevirapine and Lamivudine in Patients with HIV-1 Infection.
Sabo J, Lamson M, Leitz G, et al  
 AAPS PharmSci 2000;2(1):E1
 Abstract 		 
NVP/EFV/DDI
           
  Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily
regimen for patients with HIV infection.
 Jordan WC, Jefferson R, Yemofio F, et al
J Natl Med Assoc. 2003 Dec; 95(12): 1152-7.
 Abstract
NVP/Etravirine
           
  Susceptibility to Etravirine of HIV-1 subtype C isolates from Nevirapine/Efavirenz-experienced patients: comparative interpretation of ANRS and STANFORD algorithms.
 Fleury HJ, Anquetil D, Deshpande A, et al 
AIDS Res Hum Retroviruses. 2012 Apr 20.
 Abstract
NVP/TNF/EMT
           
  FULL-TEXT ARTICLE
Effectiveness of a Treatment Switch to Nevirapine plus Tenofovir and Emtricitabine (or Lamivudine) in Adults with HIV-1 Suppressed Viremia.
 Llibre JM, Bravo I, Ornelas A, et al
PLoS One. 2015 Jun 24;10(6):e0128131.
 Paper

Evaluation of the Safety and Effectiveness of Nevirapine Plus Coformulated Tenofovir/Emtricitabine as First-Line Therapy in Routine Clinical Practice.
 Vallecillo G, Domingo P, Mallolas J,  et al
AIDS Res Hum Retroviruses. 2011 Jul 26
 Abstract

NVP/STV/3TC
           
 
Management of HIV-1 Infection With a Combination of Nevirapine, Stavudine, and Lamivudine: A Preliminary Report on the Nigerian Antiretroviral Program.
 Idigbe EO, Adewole TA, Eisen G, et al  
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):65-69.
 Abstract
 
FULL-TEXT ARTICLE
 Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1
 van Leth F , Phanuphak P Stroes  E , et al  
PLoS Medicine Vol 1, No 1
 Paper

FULL-TEXT PDF ARTICLE
 Effectiveness and tolerability of nevirapine, stavudine, and lamivudine in clinical practice.
 Yozviak JL, Eric Doerfler R, Woodward WC.
HIV Clin Trials 2001 Nov-Dec;2(6):474-476
 PDF Paper

Nevirapine or Efavirenz Combined with Two Nucleoside Reverse Transcriptase Inhibitors Compared to HAART: A Meta-Analysis of Randomized Clinical Trials.
 Torre D, Tambini R, Speranza F, et al. 
HIV Clin Trials 2001 Mar-Apr;2(2):113-21
Abstract

Efficacy of nevirapine-based haart in hiv-1-infected, treatment-naive persons with high and low baseline viral loads
 Raffi F, Reliquet V, Podzamczer D, Pollard RB.
 HIV Clin Trials 2001 Jul-Aug;2(4):317-22
Abstract

 
NVP/ZDV/DDI vs ZDV/DDI
           
  Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial.
 NIAID Clinical Trials Group Protocol 241 Investigators.
D'Aquila RT, Hughes MD, Johnson VA, et al.
 Ann Intern Med 1996 Jun 15;124(12):1019-30
Abstract 		  
NVP/ZDV/3TC
           
  Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
 Munderi P, Walker AS, Kityo C,  et al
HIV Med. 2010 Feb
Abstract 		  
STV/DDI/NVP
           
  Immunologic response to antiretroviral treatment with combined stavudine, didanosine and nevirapine.
 Reliquet V, Robillard N, Perre P, et al
Presse Med 2001 Jul 7-3;30(23):1143-7
Abstract 		 
Miscellaneous Combinations
           
 
Clinical experience with nevirapine combined with tenofovir plus emtricitabine or lamivudine-containing regimens in HIV-infected subjects.
 Smith DE, Chan DJ, Maruszak H, Jeganathan S.
 Int J STD AIDS. 2011 Apr;22(4):228-30
 Abstract

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
 Mbuagbaw LC, Irlam JH, Spaulding A,  et al
Cochrane Database Syst Rev. 2010 Dec 8;12:CD004246.
 Abstract

Using of nevirapine is associated with intermediate and reduced response to etravirine among HIV-infected patients who experienced virologic failure in a resource-limited setting.
 Kiertiburanakul S, Wiboonchutikul S, Sukasem C,  et al 
J Clin Virol. 2010 Feb 24
 Abstract

 
Post-Exposure Prophylaxis
       
 
Tolerance of a Short Course of Nevirapine, Associated With 2 Nucleoside Analogues, in Postexposure Prophylaxis of HIV.
Rey D, Partisani M, Hess-Kempf G, et al 
J Acquir Immune Defic Syndr. 2004 Dec 1;37(4):1454-6.
Abstract

Drug-induced aminotransferase alterations during antiretroviral HIV post-exposure prophylaxis.
Puro V, Soldani F, De Carli G, et al 
AIDS. 2003 Sep 5;17(13):1988-90.
 Abstract
Dosing
       
 
Finding of nevirapine extended release tablet remnants in stools does not threaten the success of combination antiretroviral therapy
 Stephan C, León W.
HIV Med. 2013 Sep 23.
Abstract

Considerations on the New Nevirapine: Switching Patients from Twice-Daily to Once-Daily.
 Ward D, Slim J.  
J Int Assoc Physicians AIDS Care (Chic). 2013 Feb 28
 Abstract

Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment.
Yone EW, Kengne AP.
HIV AIDS (Auckl). 2012;4:181-4.
Abstract


 Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
 Calmy A, Vallier N, Nguyen A, Lange JM,  et al
Antivir Ther. 2009;14(7):931-938.
 Abstract

Once- or twice-daily dosing of nevirapine in HIV-infected adults: a population pharmacokinetics approach.
 Moltó J, Valle M, Miranda C ,et al
J Antimicrob Chemother. 2008 Jun 30.
Abstract
 
Once-daily nevirapine dosing: a pharmacokinetics, efficacy and safety review.
 Cooper C, van Heeswijk R.
HIV Med. 2007 Jan;8(1):1-7.
 Abstract
Adherence
       
 
Home deliveries: Implications for adherence to nevirapine in a PMTCT programme in rural Malawi.
 Kasenga F, Hurtig AK, Emmelin M.
AIDS Care. 2007 May;19(5):646-52.
 Abstract

 
NVP  Main Page Journal Main Page Main New/Newsworthy  Home Page

Nevirapine Journal Data
Adolescent/Adult Indications